Pharmaron Beijing Co., Ltd. Share Price
Equities
300759
CNE100003JW4
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.30 CNY | -0.25% |
|
+3.99% | +10.09% |
| 04-01 | Nomura Adjusts Pharmaron Beijing's Price Target to HK$27.33 From HK$26.63, Keeps at Buy | MT |
| 04-01 | Nomura Adjusts Pharmaron Beijing's Price Target to 35.53 Yuan From 34.62 Yuan, Keeps at Buy | MT |
| Capitalization | 52.86B 7.75B 6.57B 6.06B 5.71B 10.65B 723B 10.82B 71.03B 27.8B 347B 29.09B 28.48B 1,232B | P/E ratio 2026 * |
27.4x | P/E ratio 2027 * | 22.4x |
|---|---|---|---|---|---|
| Enterprise value | 55.74B 8.18B 6.93B 6.39B 6.02B 11.23B 762B 11.41B 74.9B 29.32B 366B 30.67B 30.03B 1,299B | EV / Sales 2026 * |
3.41x | EV / Sales 2027 * | 2.88x |
| Free-Float |
48.56% | Yield 2026 * |
0.82% | Yield 2027 * | 0.97% |
| 1 day | -0.25% | ||
| 1 week | +3.99% | ||
| Current month | +11.87% | ||
| 1 month | +12.63% | ||
| 3 months | -4.89% | ||
| 6 months | +4.16% | ||
| Current year | +10.09% |
| 1 week | 30.13 |  | 32.11 |
| 1 month | 24.88 | | 32.11 |
| Current year | 24.88 | | 34.55 |
| 1 year | 21.78 | | 37.63 |
| 3 years | 17.7 | | 37.63 |
| 5 years | 17.7 | | 108.71 |
| 10 years | 4.08 | | 108.71 |
| Manager | Title | Age | Since |
|---|---|---|---|
Xiao Qiang Lou
PSD | President | 57 | - |
Bei Zheng
PRN | Corporate Officer/Principal | 59 | 26/10/2016 |
Bo Liang Lou
CEO | Chief Executive Officer | 62 | 26/10/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Bo Liang Lou
CHM | Chairman | 62 | 26/10/2016 |
Bei Zheng
BRD | Director/Board Member | 59 | 26/10/2016 |
Ke Xin Yang
CHM | Chairman | 64 | 26/10/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.25% | +3.99% | +36.62% | -15.41% | 7.76B | |
| +0.91% | +4.95% | -1.26% | -9.56% | 47.33B | |
| +3.14% | +2.34% | +33.76% | +20.65% | 34.38B | |
| +1.71% | +3.03% | +19.19% | -12.27% | 29.42B | |
| +1.46% | +4.28% | +28.49% | +25.47% | 28.39B | |
| +3.69% | +56.79% | +317.65% | +517.38% | 29.13B | |
| -1.39% | +1.91% | +3,364.74% | +3,940.77% | 14.89B | |
| -3.27% | +3.60% | +56.97% | +191.93% | 15.44B | |
| -0.55% | -0.25% | +70.28% | +165.63% | 14.85B | |
| +1.40% | +6.34% | +36.91% | +12.91% | 14.22B | |
| Average | +0.62% | +9.42% | +396.34% | +483.75% | 23.58B | |
| Weighted average by Cap. | +1.18% | +10.14% | +273.78% | +338.65% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.34B 2.4B 2.03B 1.87B 1.76B 3.29B 223B 3.34B 21.95B 8.59B 107B 8.99B 8.8B 381B | 18.83B 2.76B 2.34B 2.16B 2.03B 3.79B 257B 3.86B 25.3B 9.9B 124B 10.36B 10.15B 439B |
| Net income | 2.07B 304M 257M 237M 224M 417M 28.3B 424M 2.78B 1.09B 13.59B 1.14B 1.12B 48.24B | 2.52B 370M 313M 289M 273M 508M 34.49B 517M 3.39B 1.33B 16.56B 1.39B 1.36B 58.8B |
| Net Debt | 2.88B 423M 358M 330M 311M 580M 39.39B 590M 3.87B 1.52B 18.91B 1.59B 1.55B 67.14B | 1.36B 200M 170M 156M 147M 275M 18.65B 279M 1.83B 718M 8.96B 751M 735M 31.8B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/04/26 | 31.30 ¥ | -0.25% | 49,221,160 |
| 14/04/26 | 31.38 ¥ | +2.31% | 35,025,070 |
| 13/04/26 | 30.67 ¥ | -1.41% | 28,984,810 |
| 10/04/26 | 31.11 ¥ | +1.83% | 48,083,000 |
| 09/04/26 | 30.55 ¥ | +0.49% | 45,914,030 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300759 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition